Norovirus Infections
14
1
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.1%
1 terminated out of 14 trials
90.9%
+4.4% vs benchmark
7%
1 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (14)
A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
Norovirus Challenge Study
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
Human Breastmilk in Young Children With Norovirus Infection of the Gut
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)